About us

SYNNOVE PHARMACEUTICALS PRIVATE LIMITED is a privately owned company established in 2017 that aims to provide synergies that perform and provide medical solutions through quality medicines at affordable costs.

SYNNOVE PHARMACEUTICALS PRIVATE LIMITED is led by the able guidance of Management having over 25 years of experience and has excellent reputation of providing efficient services in the Pharmaceuticals Industry.

At Synnove, We aim to establish our presence in the field of Dermatology, Allergy by building Trust through our never ending dedication, work culture where customers are at the fore front of all priorities. Our Brands include Halosyn, Halosyn S, Berox & Berox AD form the core treatment in Dermatology segments like STEROID RESPONSIVE DERMATOSES, ACNE which are very commonly occurring lifestyle disorders.

SYNNOVE PHARMACEUTICALS PRIVATE LIMITED is established with the sole objective of having “PATIENT FIRST APPROACH” by partnering with Medical Professionals and offering range of medicines at affordable costs without compromising on providing Quality Treatments.

CUSTOMER SATISFACTION:
SYNNOVE PHARMACEUTICALS PRIVATE LIMITED has allied with manufacturing companies that have similar policies towards their Customers and synergize with us in achieving our objective.

We aim to ensure that our Products are easily available to the Patients through Retailers and Stockists across all corners.

ETHICS: Our Policies shall be the mirror of our behavior, as we build our customers ensuring high level of integrity with our stakeholders i.e. Doctors, Stockists, Retailers and Patients.

EMPLOYEE SATISFACTION: We aim to build a energetic Field Force who shall be motivated to drive our objectives with all stake holders with the support of Management and ensure transparency through open communication.

CSR: We aim to engage ourselves to enhance the image of the Organization through OPD Camps, offering need based help to charitable dispensaries and organize Patient Awareness programs to increase the well being of the Patients.

Comments are closed